Saturday, April 29, 2017 10:36:48 AM
Study shows benefit in children with CNS-relapsed ALL
In a secondary analysis of the phase I/IIa CHP 959 study, looking only at children with CNS involvement, 71% remain in complete remission a median of 11 months after the therapy, reported Mala Talekar, MD, from Children's Hospital of Philadelphia.
Presenting the findings at the annual meeting of the American Society of Pediatric Hematology/Oncology here, Talekar said the "remarkable milestone" underscores the potential for CTL019
HTTPS://www.medpagetoday.com/meetingcoverage/additionalmeetings/64895
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM